Heart Valve Marketing: Reaching Cardiovascular Surgeons and Interventionalists

The Heart Valve Device Market: Surgical and Transcatheter

Heart valve disease affects millions of people worldwide, and the devices used to treat it - from traditional surgical heart valves to next-generation transcatheter platforms - represent one of the most dynamic and commercially significant segments of the cardiovascular device industry. The global heart valve market is projected to exceed $15 billion by 2028, driven by aging populations, expanding transcatheter indications, and growing awareness of valvular heart disease.

Marketing heart valve devices requires navigating a market that spans two fundamentally different approaches: surgical valve replacement (performed through open-heart surgery or minimally invasive techniques) and transcatheter valve intervention (performed through catheter-based delivery). Each approach targets different physician specialties, involves different hospital decision-making processes, and demands different marketing strategies.

At Buzzbox Media in Nashville, we help heart valve device companies build marketing programs that reach the right physicians, communicate clinical evidence effectively, and drive commercial growth. This guide covers the full spectrum of heart valve marketing, from surgical tissue valves to transcatheter platforms.

Understanding the Heart Valve Product Landscape

Surgical Heart Valves

Surgical heart valves remain the standard of care for many patients, particularly younger patients who may benefit from mechanical valves and patients with complex anatomy unsuitable for transcatheter approaches. The surgical valve market includes:

• Mechanical valves: Durable but require lifelong anticoagulation with warfarin. Used primarily in younger patients who can tolerate anticoagulation and benefit from the valve's indefinite durability.
• Bioprosthetic (tissue) valves: Made from bovine pericardium or porcine valve tissue. Do not require long-term anticoagulation but have a limited lifespan (typically 10-20 years), after which they may need replacement.
• Sutureless and rapid-deployment surgical valves: A category that bridges surgical and transcatheter approaches. These valves are implanted through a surgical incision but use a self-expanding frame that reduces cross-clamp time and simplifies the procedure.

Transcatheter Heart Valves

Transcatheter valves are delivered through catheter-based systems, typically via the femoral artery or other vascular access points, avoiding the need for open-heart surgery. The transcatheter valve market includes:

• Transcatheter aortic valve replacement (TAVR): The largest transcatheter valve category, approved for the full spectrum of surgical risk in the aortic position.
• Transcatheter mitral valve repair: Edge-to-edge repair devices that reduce mitral regurgitation without valve replacement.
• Transcatheter mitral valve replacement (TMVR): An emerging category with several devices in clinical trials.
• Transcatheter tricuspid valve devices: Early-stage devices addressing the undertreated tricuspid regurgitation market.
• Valve-in-valve procedures: Using transcatheter valves to treat failed surgical bioprosthetic valves, avoiding repeat open-heart surgery.

Two Audiences: Cardiovascular Surgeons and Interventional Cardiologists

Heart valve marketing must effectively reach two distinct physician audiences that approach valve disease from different perspectives and training backgrounds.

Cardiovascular Surgeons

Cardiac surgeons have been treating valve disease for decades through open surgical approaches. They evaluate heart valves based on:

• Implant technique and handling: How the valve sews into the annulus, the quality of the sewing cuff, and the predictability of the implantation process.
• Hemodynamic performance: Effective orifice area (EOA), mean gradient, and how the valve performs across different annular sizes, particularly in small annuli where patient-prosthesis mismatch is a concern.
• Durability: Long-term valve performance data, including structural valve deterioration (SVD) rates and freedom from reoperation.
• Anti-calcification technology: For tissue valves, the treatment process used to reduce calcification and extend valve life.
• Repair-friendly features: Surgeons often prefer repair over replacement when possible. Devices and techniques that support mitral and tricuspid valve repair resonate strongly.

Interventional Cardiologists

Interventional cardiologists performing transcatheter valve procedures evaluate devices differently:

• Delivery system design: Profile (sheath size), flexibility, navigability, and ease of valve deployment and positioning.
• Repositionability and retrievability: The ability to adjust valve position after initial deployment and to retrieve the device if needed.
• Imaging compatibility: How well the valve appears under fluoroscopy and echocardiography during the procedure.
• Paravalvular leak performance: The seal between the valve and the native annulus.
• Access site options: Transfemoral, transapical, transaxillary, and transcaval access compatibility.

The Heart Team Dynamic

Increasingly, valve disease treatment decisions are made by multidisciplinary heart teams that include both surgeons and interventional cardiologists, along with imaging specialists and anesthesiologists. Your marketing must address the heart team collectively while also providing specialty-specific content for each member.

This means developing separate but complementary campaigns:

• Surgical-focused campaigns emphasizing implant technique, hemodynamics, and durability for the surgical valve audience.
• Interventional-focused campaigns emphasizing delivery system performance, procedural outcomes, and expanding indications for the transcatheter valve audience.
• Heart team-focused campaigns promoting multidisciplinary patient selection, shared decision-making, and comprehensive valve programs.

Clinical Messaging for Heart Valve Devices

Building Your Evidence Narrative

Heart valve marketing must be anchored in clinical evidence. The specific data points that matter depend on your product type and competitive positioning:

For surgical tissue valves:

• Freedom from structural valve deterioration at 10, 15, and 20 years
• Freedom from reoperation and valve-related mortality
• Hemodynamic performance across annular sizes, with specific attention to small annuli (19mm, 21mm)
• Anti-calcification treatment data and the underlying preservation technology
• Comparative data versus competing surgical tissue valves

For surgical mechanical valves:

• Thrombogenicity profile and recommended INR ranges
• Hemodynamic performance and effective orifice area
• Long-term freedom from valve-related events
• Acoustic profile (audible click is a patient concern)

For transcatheter valves:

• Pivotal trial results for all-cause mortality, stroke, and composite endpoints
• Paravalvular leak rates and conduction disturbance rates
• Long-term durability data (increasingly the critical battleground as TAVR moves to lower-risk, younger patients)
• Delivery system performance metrics and access site complication rates
• Subgroup analyses for specific anatomies (bicuspid valves, large annuli, heavily calcified anatomy)

Regulatory Compliance in Valve Marketing

All clinical claims in heart valve marketing materials must comply with FDA requirements for on-label promotion, fair balance, and substantiation. This is particularly important for:

• Durability claims, which must be supported by long-term follow-up data from controlled studies or registries.
• Comparative claims against competing valves, which require head-to-head evidence or rigorously conducted indirect comparisons.
• Indication-specific claims, particularly as transcatheter valves receive expanded indications for lower-risk populations.
• Claims about valve-in-valve compatibility, which must reflect the specific testing and labeling for your device.

Work closely with your regulatory affairs and medical affairs teams to establish a medical-legal-regulatory (MLR) review process for all promotional materials. For more on navigating medical device marketing regulations, see our medical device marketing guide.

Digital Marketing Strategy for Heart Valve Devices

SEO for Heart Valve Companies

Search engine optimization is a powerful long-term investment for heart valve companies. Both physicians and patients actively search for information about valve disease treatment options, clinical evidence, and device comparisons.

Physician-targeted keyword opportunities:

• "TAVR vs SAVR outcomes," "tissue valve durability comparison," "mechanical vs bioprosthetic valve selection"
• "[valve name] hemodynamic data," "[trial name] long-term results," "valve-in-valve feasibility"
• "aortic valve replacement options 2026," "mitral valve repair techniques," "tricuspid valve intervention"
• "small annulus aortic valve prosthesis," "patient-prosthesis mismatch prevention"

Patient-targeted keyword opportunities:

• "heart valve replacement options," "TAVR vs open heart surgery recovery," "tissue valve vs mechanical valve"
• "aortic stenosis symptoms," "mitral valve regurgitation treatment," "life after heart valve replacement"
• "heart valve surgery recovery time," "minimally invasive valve surgery"

Build comprehensive content for each valve position (aortic, mitral, tricuspid, pulmonary) and each treatment approach (surgical, transcatheter). Publish clinical evidence summaries, procedural technique articles, and patient education content on a regular cadence. For a deeper dive, explore our healthcare SEO services.

Video Marketing for Heart Valves

Heart valve procedures are inherently visual, making video content an essential component of your digital strategy:

• Surgical technique videos: Expert surgeons demonstrating valve implantation technique, including tips for optimal sizing, positioning, and hemostasis.
• Transcatheter procedure videos: Step-by-step procedural walkthroughs showing device preparation, delivery, deployment, and post-deployment assessment.
• Mechanism of action animations: 3D animations showing how your valve functions within the heart, how the delivery system works, and how the sealing mechanism prevents paravalvular leak.
• KOL interviews: Expert physicians discussing their clinical experience, patient selection approach, and evaluation of your device's performance.
• Patient stories: Where permitted, patient testimonials showing the impact of valve treatment on quality of life and daily function.

Email Marketing

Segment your email communications by physician specialty, procedure type, and level of engagement:

• Surgeons: Focus on surgical technique content, hemodynamic data, durability updates, and new product introductions.
• Interventional cardiologists: Emphasize transcatheter clinical evidence, procedural tips, case studies, and new indication updates.
• General cardiologists: Provide referral-oriented content about identifying valve disease candidates, updated treatment guidelines, and when to refer to a valve specialist.
• Hospital administrators: Share health economics data, reimbursement updates, and program development resources.

KOL Engagement in Heart Valve Marketing

Identifying Valve KOLs

The heart valve space has distinct KOL communities for surgical and transcatheter approaches. Map your KOLs across both groups:

• Surgical KOLs: Prominent cardiac surgeons who publish on valve surgery outcomes, lead surgical quality registries (STS database), and hold leadership positions in the STS and AATS.
• Transcatheter KOLs: Interventional cardiologists who lead TAVR and transcatheter mitral programs, serve as trial investigators, and present at TCT and ACC.
• Imaging KOLs: Echocardiographers and CT imaging experts who influence pre-procedural planning protocols and intra-procedural guidance standards.
• Guideline writers: Physicians who serve on ACC/AHA valve disease guideline committees. Their recommendations shape clinical practice and device utilization for years.

KOL Activation Strategies

• Advisory boards: Bring surgical and transcatheter KOLs together to provide input on product development, clinical strategy, and commercial positioning. Cross-discipline advisory boards foster understanding and collaboration.
• Proctoring and precepting: KOLs who proctor new users are among your most effective advocates. Invest in structured proctoring programs at targeted hospitals.
• Peer-to-peer education: Organize case-based learning events where KOLs share their experience with your valve. Virtual and in-person formats both work, but combine them for maximum reach.
• Publication support: Support KOLs in publishing clinical data, case series, and expert reviews in high-impact journals. These publications become the foundation of your evidence-based marketing.
• Content collaboration: Create videos, podcasts, and written content with KOLs that can be distributed through your digital channels.

Conference Strategy for Heart Valve Companies

Prioritize These Conferences

• STS Annual Meeting: The premier cardiac surgery conference. Essential for surgical valve companies and for transcatheter companies engaging the surgical side of the heart team.
• TCT: The flagship interventional cardiology conference. Critical for transcatheter valve companies presenting clinical data and demonstrating new technologies.
• ACC Scientific Sessions: Broad cardiology audience with significant valve disease content, including guideline updates and late-breaking trials.
• AATS Annual Meeting: The American Association for Thoracic Surgery meeting draws top cardiac surgeons focused on innovative surgical techniques.
• TVT (Transcatheter Valve Therapies): A focused structural heart conference with deep coverage of transcatheter valve technologies.
• ESC and EuroPCR: Essential for European market strategy.

Conference Best Practices for Valve Companies

• Submit late-breaking clinical data to the most prestigious presentation slots. A TCT late-breaker or an STS featured presentation shapes the narrative for your device.
• Host satellite symposia featuring your KOLs presenting clinical data with live case examples.
• Offer hands-on valve handling workshops where surgeons and interventional cardiologists can experience your device's implant characteristics and delivery system.
• Coordinate your booth messaging with your clinical data presentations. When your trial results are presented at 2:00 PM, your booth team should be prepared to discuss them by 2:15.
• Plan pre-conference and post-conference digital campaigns that extend the reach of your conference presence to physicians who could not attend.

Hospital Program Development and Sales Enablement

Supporting Valve Programs

Heart valve device companies that offer program development support build deeper hospital relationships and create sustainable competitive advantages:

• Heart team formation support: Help hospitals establish or formalize their heart valve team, including protocols for case conferences, patient evaluation pathways, and shared decision-making.
• Volume growth support: Assist hospitals in identifying underdiagnosed valve disease patients in their community through screening initiatives and referral network development.
• Quality improvement: Provide benchmarking data and quality metrics that help valve programs track outcomes and improve performance.
• Patient education resources: Offer co-branded patient education materials, decision aids, and online resources that hospitals can use to inform patients about their treatment options.

Sales Enablement Materials

Equip your sales team with the tools they need to support physician and hospital conversations:

• Clinical sell sheets: One-page summaries of key clinical data for each valve product and indication.
• Value dossiers: Comprehensive documents for value analysis committee presentations covering clinical evidence, health economics data, competitive comparisons, and implementation support.
• Sizing guides: Detailed valve sizing resources, including echocardiographic measurement protocols and CT sizing algorithms for transcatheter valves.
• Competitive comparisons: Internal-only battle cards addressing head-to-head questions about hemodynamics, durability, delivery system design, and clinical evidence versus specific competitors.
• Case study libraries: Documented cases demonstrating successful outcomes in various anatomies and clinical scenarios.

Health Economics and Reimbursement

Heart valve procedures involve significant cost, and hospital purchasing decisions increasingly require health economics justification:

• Total episode-of-care cost: Compare the total cost of treatment with your device versus alternatives, including the procedure itself, hospital stay, complications, and follow-up care.
• Length of stay analysis: Shorter stays mean lower hospital costs. Document your device's impact on length of stay compared to alternatives.
• Readmission reduction: Lower complication rates and readmission rates translate to economic value for hospitals operating under bundled payment and value-based care models.
• Coding and reimbursement guides: Help hospitals navigate the DRG codes, CPT codes, and payment mechanisms relevant to your valve procedures.
• Lifetime cost modeling: For tissue valves, model the expected timeline and cost of potential reintervention due to structural valve deterioration. Compare against the lifelong anticoagulation costs of mechanical valves.

Emerging Trends in Heart Valve Marketing

Valve Durability as the Central Battleground

As transcatheter approaches expand to younger, lower-risk patients, valve durability has become the defining competitive issue. Patients who receive a valve in their 60s or 70s may live with it for 20-30 years. Marketing programs must put long-term data front and center and address physician concerns about structural valve deterioration transparently.

Valve-in-Valve and Lifetime Management

The concept of lifetime valve management - planning a patient's valve treatment strategy across their entire lifetime, potentially including initial surgical valve, subsequent transcatheter valve-in-valve, and beyond - is reshaping how physicians think about valve selection. Marketing that positions your device within a lifetime management framework, rather than as a single-procedure solution, resonates with forward-thinking physicians.

Digital Health Integration

Heart valve devices are beginning to incorporate digital health monitoring through patient-reported outcome apps, remote echocardiographic assessment, and wearable hemodynamic monitoring. Marketing these digital capabilities alongside the physical device adds a new dimension to the value proposition.

Artificial Intelligence in Valve Planning

AI-powered tools for valve sizing, patient selection, and outcome prediction are emerging as differentiators for valve companies. Marketing these tools requires explaining their clinical utility without overclaiming their predictive accuracy.

Heart valve device marketing rewards companies that balance scientific rigor with strategic creativity. Whether you are marketing a proven surgical valve or launching a novel transcatheter platform, the principles remain the same: know your physician audience, lead with clinical evidence, and build a marketing program that supports every stakeholder in the treatment decision.

Looking for a marketing partner with heart valve device experience? Contact the Buzzbox Media team to start the conversation.